Achaogen's lead 抗生物質 後継するs two 重要な 熟考する／考慮するs; 株 急に上がる
Dec 12 (Reuters) - Achaogen Inc's lead 抗生物質 was successful in two 重要な 熟考する／考慮するs, spurring the company to proceed with regulatory submissions in the 部隊d 明言する／公表するs and Europe, and 株 急に上がるd 76 パーセント to their highest in more than a year and half.
In a late-行う／開催する／段階 熟考する／考慮する, CARE, 伴う／関わるing 患者s with serious 感染s 予定 to carbapenem-抵抗力のある enterobacteriaceae (CRE), 治療 with the 麻薬, plazomicin, resulted in lower mortality 率s or serious 複雑化s, compared with colistin therapy, one of the few 抗生物質s still used to 扱う／治療する CRE.
CRE is 比較して rare, but the U.S. 中心s for 病気 支配（する）／統制する and 予防 has みなすd it a "nightmare bacteria" because it spreads easily, is ますます 抵抗力のある to 存在するing 抗生物質s, and can kill up to half of its 犠牲者s.
Data shows there were about 65,000-75,000 事例／患者s of CRE in the 部隊d 明言する／公表するs last year, the company said on a 会議／協議会 call with 分析家s.
In a separate late-行う／開催する／段階 裁判，公判 called EPIC, plazomicin was 設立する to be as 効果的な as the 幅の広い spectrum 抗生物質, meropenem, in 患者s with 複雑にするd urinary tract 感染s (cUTI) and 激烈な／緊急の pyelonephritis, Achaogen said.
A cUTI is associated with an underlying 条件, which 増加するs the 危険 of failing therapy. Pyelonephritis typically occurs when bacteria migrate from the bladder to the 腎臓, 感染させるing the 組織／臓器.
Achaogen said it planned to sub mit a marketing 使用／適用, 含むing data from both 熟考する／考慮するs, to the U.S. Food and 麻薬 行政 in the second half of 2017 and the European 薬／医学s 機関 in 2018.
The biotech company's 株 jumped to $9.25 in morning 貿易（する）ing on Monday. Up to Friday's の近くに, Achaogen's 在庫／株 had fallen 8.54 パーセント since the start of the year.
William Blair's Katherine Xu has 予測（する） 頂点（に達する） plazomicin sales of $270 million for cUTI and $70 million for CRE in 2031, if 認可するd, in a （弁護士の）依頼人 公式文書，認める published in November.
The plazomicin program is 基金d in part with an up to $103.8 million 契約 from the Biomedical 前進するd 研究 and 開発 当局, or BARDA, a 部隊 of U.S. Department of Health and Human Services.
Antimicrobial 抵抗力のある, or superbug, 感染s, kill hundreds of thousands of people a year and has been 述べるd by the World Health Organization as "one of the biggest health challenges of the 21st century." (報告（する）／憶測ing by Natalie Grover in Bengaluru; Editing by Anil D'Silva and Martina D'Couto)
